[go: up one dir, main page]

AR040779A1 - Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion - Google Patents

Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion

Info

Publication number
AR040779A1
AR040779A1 AR20030102791A ARP030102791A AR040779A1 AR 040779 A1 AR040779 A1 AR 040779A1 AR 20030102791 A AR20030102791 A AR 20030102791A AR P030102791 A ARP030102791 A AR P030102791A AR 040779 A1 AR040779 A1 AR 040779A1
Authority
AR
Argentina
Prior art keywords
alkyl
formulation
group
compound
prepare
Prior art date
Application number
AR20030102791A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR040779A1 publication Critical patent/AR040779A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de tiazol anilina de la fórmula (1) en la que: el tiazol está en orto con respecto al N; R1 se selecciona del grupo constituido por halógeno, alquilo C1-5, CH2F, CHF2; R2 se selecciona del grupo constituido por H, alquilo C1-5, arilo, halógeno, hidroxi y alcoxi; R3 se selecciona del grupo constituido por H, alquilo C1-5, cicloalquilo, cicloalquil-alquilo C1-5, alquenilo C2-4,alquenil C2-4-arilo; cicloalquil alquilo C1-5 y alquil C1-4-arilo, que pueden estar opcionalmente sustituidos independientemente con un sustituyente seleccionado del grupo constituido por halógeno, nitro, alquilo C1-4 halosustituido, alquilo C1-4, amino, amino mono- o di-sustituido con alquilo C1-4, ORa, -C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)mRa, C(O)NR6R7, C(O)OH, C(O)ORa, S(O)2NR6R7 y NHS(O)2Ra; R6 y R7 se seleccionan del grupo constituido por H y alquilo C1-4 o R6 y R7 juntos forman un anillo de 5 a 7 elementos, anillo que puede contener opcionalmente un heteroátomo adicional seleccionado de O, N o S y cuyo anillo puede estar opcionalmente sustituido; n es 1 o 2; e independientemente m es 1 o 2. Uso de un compuesto de fórmula (1) para preparar una formulación farmacéutica de utilidad en un procedimiento de antagonización del receptor muscarínico M3 de acetilcolina y dicha formulación. Recipiente provisto de una válvula dosificadora que contiene la formulación farmacéutica y dispositivo adaptado para la administración intranasal de dicha formulación que comprende dicho recipiente.
AR20030102791A 2002-08-06 2003-08-04 Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion AR040779A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40175602P 2002-08-06 2002-08-06

Publications (1)

Publication Number Publication Date
AR040779A1 true AR040779A1 (es) 2005-04-20

Family

ID=31495981

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102791A AR040779A1 (es) 2002-08-06 2003-08-04 Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion

Country Status (9)

Country Link
US (1) US20050277676A1 (es)
EP (1) EP1549278A4 (es)
JP (1) JP2006505517A (es)
AR (1) AR040779A1 (es)
AU (1) AU2003261392A1 (es)
PE (1) PE20040892A1 (es)
TW (1) TW200410951A (es)
UY (1) UY27927A1 (es)
WO (1) WO2004012684A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200811172A (en) 2003-10-14 2008-03-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046114A1 (es) * 2003-10-17 2005-11-23 Glaxo Group Ltd Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
JP2007528416A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
EP1723109A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723112A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7384946B2 (en) * 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1765339A4 (en) * 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006024483A1 (en) * 2004-09-01 2006-03-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with muscarinic acetylcholine receptor 3 (acm3)
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2008537931A (ja) 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
JP2008533028A (ja) 2005-03-10 2008-08-21 セラヴァンス， インコーポレーテッド ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (en) 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
JP2007280195A (ja) * 2006-04-10 2007-10-25 Pfu Ltd 内部統制システム
US20100144801A1 (en) * 2006-10-03 2010-06-10 Naresh Kumar Muscarinic receptor antagonists
CA2678193A1 (en) 2007-02-09 2008-08-14 Astellas Pharma Inc. Aza-bridged-ring compound
UY31636A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
HUE043496T2 (hu) * 2014-06-06 2019-08-28 Astellas Pharma Inc 2-aminotiazol származék hólyag/húgyúti betegségek megelõzésében vagy kezelésében történõ alkalmazásra

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2542822B1 (fr) * 1983-03-15 1985-07-12 Procedes Tech Const Dispositif de regulation d'une eolienne comportant un panneau de commande d'effacement basculant sous la commande d'un panneau auxiliaire
US20020052007A1 (en) * 1992-02-03 2002-05-02 Chang Kwen Jen Diarylmethylbenzylpiperazines and corresponding halobenzyl derivatives
GB9909612D0 (en) * 1999-04-26 1999-06-23 Cancer Res Campaign Tech N-protected amines and their use as prodrugs
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2003053941A2 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases

Also Published As

Publication number Publication date
UY27927A1 (es) 2003-12-31
AU2003261392A8 (en) 2004-02-23
EP1549278A4 (en) 2005-12-14
TW200410951A (en) 2004-07-01
AU2003261392A1 (en) 2004-02-23
JP2006505517A (ja) 2006-02-16
US20050277676A1 (en) 2005-12-15
PE20040892A1 (es) 2004-11-19
EP1549278A2 (en) 2005-07-06
WO2004012684A2 (en) 2004-02-12
WO2004012684A3 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
AR040779A1 (es) Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
ECSP12011867A (es) Derivados bencimidazol-imidazol
AR013493A1 (es) COMPUESTO DE QUINOLONA, SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO Y COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE
AR106013A1 (es) Conjugados de anticuerpos modificados con cisteína
AR109033A2 (es) Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso
AR061134A1 (es) Derivados de tioxantina
PE20040479A1 (es) Inhibidores de proteasa del vih y composiciones que los contienen
CU23288B7 (es) DERIVADOS DE TROPANO ÃsTILES EN TERAPIA
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
ES2578302T3 (es) Compuestos de 5,6-dihidro-1H-piridin-2-ona
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
ES2186251T3 (es) Nuevos derivados de acilguanidina como inhibidores de la resorcion de los huesos y como antagonistas de receptores de vitronectina.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
CO5450245A1 (es) Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas
AR042941A1 (es) Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1)
BR112016014595A8 (pt) material à base de sólido para uso tópico sobre a pele,composição aquosa e método de produção do mesmo.
BR112012033465A2 (pt) método para preparar um composto
MX2022002339A (es) Derivados de alfa-d-galactopiranosido.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR044342A1 (es) Derivados de bencimidazol
AR058077A1 (es) Derivados de acidos fenoxiaceticos
AR059886A1 (es) Derivados de amidas como inhibidores de renina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal